Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 28
Filter
1.
PLoS One ; 19(5): e0303058, 2024.
Article in English | MEDLINE | ID: mdl-38728289

ABSTRACT

BACKGROUND: Shared decision-making (SDM) refers to a collaborative process in which clinicians assist patients in making medically informed, evidence-based decisions that align with their values and preferences. There is a paucity of literature on SDM in dermatology. OBJECTIVE: We aim to assess whether male and female psoriasis patients evaluate their clinicians' engagement in SDM differently across different age groups. METHODS: Cross-sectional study using data from the 2014-2017 and 2019 Medical Expenditure Panel Surveys (MEPS). RESULTS: A weighted total of 7,795,608 psoriasis patients were identified. SDM Scores ranged from 1 to 4, with 4 representing the most favorable patient evaluation of their clinicians' engagement in SDM. We conducted multivariate linear regression to compare mean SDM Scores in male psoriasis patients versus female psoriasis patients across different patient age groups. Female patients ages 60-69 perceived significantly greater clinician engagement in SDM compared to age-matched male patients (female patient perception of SDM 3.65 [95%CI:3.61-3.69] vs. male patient perception of SDM 3.50 [95%CI:3.43-3.58], p<0.005). The same trend of older female patients evaluating their clinicians' engagement in SDM significantly higher than their age-matched male counterparts exists for the age group >70 (p<0.005). No significant differences between male and female patients' evaluations of their clinicians' engagement in SDM were demonstrated in subjects younger than 60. All calculations were adjusted for demographic and clinical factors. CONCLUSIONS: Compared to older male psoriasis patients, older female psoriasis patients evaluated their clinicians to be more engaged in shared decision-making.


Subject(s)
Decision Making, Shared , Psoriasis , Humans , Psoriasis/psychology , Psoriasis/therapy , Male , Female , Middle Aged , Adult , Aged , Cross-Sectional Studies , Age Factors , Sex Factors , Patient Participation , Young Adult , Physician-Patient Relations , Delivery of Health Care , Adolescent , Surveys and Questionnaires , Perception
3.
N Engl J Med ; 389(10): 963-964, 2023 Sep 07.
Article in English | MEDLINE | ID: mdl-37672709
4.
Cutis ; 111(4): 170-171, 2023 04.
Article in English | MEDLINE | ID: mdl-37289689

Subject(s)
Mpox (monkeypox) , Humans
7.
Dermatol Online J ; 28(3)2022 Jun 15.
Article in English | MEDLINE | ID: mdl-36259803

ABSTRACT

Lucio phenomenon is a rare vasculopathy that can occur in patients with Hansen disease, particularly diffuse lepromatous leprosy. It is characterized by retiform purpura and necrotic ulcerations, most commonly affecting the extremities. Diagnosing Lucio phenomenon can be challenging, especially when secondary bacterial infections occur. We report a patient with Lucio phenomenon who presented with acute necrotizing fasciitis of his left upper extremity and a 10-year history of chronic ulcerations. Shortly following admission, he also developed acute kidney injury. The necrotizing fasciitis was treated with prompt surgical debridement and intravenous antibiotics. Biopsy and PCR of a right upper extremity ulcer confirmed the presence of Mycobacterium lepromatosis. Multidrug therapy and prednisone were used to treat the Lucio phenomenon. After initiating treatment, no new lesions developed, kidney function improved, and the patient underwent successful skin graft of his left upper extremity. Although corticosteroid use is controversial, our patient's marked response to multidrug therapy with prednisone highlights the importance of this regimen in severe presentations of Lucio phenomenon. To the best of our knowledge, only two other cases of Lucio phenomenon confirmed to be caused by M. lepromatosis have been reported in living patients (rather than retrospectively identified post-mortem), underscoring the importance of the presented clinical course and treatment regimen.


Subject(s)
Acute Kidney Injury , Fasciitis, Necrotizing , Panniculitis , Vascular Diseases , Male , Humans , Leprostatic Agents/therapeutic use , Prednisone/therapeutic use , Fasciitis, Necrotizing/complications , Fasciitis, Necrotizing/diagnosis , Fasciitis, Necrotizing/therapy , Drug Therapy, Combination , Retrospective Studies , Panniculitis/drug therapy , Acute Kidney Injury/etiology , Acute Kidney Injury/drug therapy , Adrenal Cortex Hormones
9.
iScience ; 23(5): 101050, 2020 May 22.
Article in English | MEDLINE | ID: mdl-32339990

ABSTRACT

Myeloid derived suppressor cells (MDSCs) are a population of immature myeloid cells that suppress adaptive immune function, yet the factors that regulate their suppressive function in patients with infection remain unclear. We studied MDSCs in patients with leprosy, a disease caused by Mycobacterium leprae, where clinical manifestations present on a spectrum that correlate with immunity to the pathogen. We found that HLA-DR-CD33+CD15+ MDSCs were increased in blood from patients with disseminated/progressive lepromatous leprosy and possessed T cell-suppressive activity as compared with self-limiting tuberculoid leprosy. Mechanistically, we found ER stress played a critical role in regulating the T cell suppressive activity in these MDSCs. Furthermore, ER stress augmented IL-10 production, contributing to MDSC activity, whereas IFN-γ allowed T cells to overcome MDSC suppressive activity. These studies highlight a regulatory mechanism that links ER stress to IL-10 in mediating MDSC suppressive function in human infectious disease.

10.
Clin Infect Dis ; 71(8): e262-e269, 2020 11 05.
Article in English | MEDLINE | ID: mdl-31732729

ABSTRACT

BACKGROUND: Mycobacterium leprae was thought to be the exclusive causative agent of leprosy until Mycobacterium lepromatosis was identified in a rare form of leprosy known as diffuse lepromatous leprosy (DLL). METHODS: We isolated M. lepromatosis from a patient with DLL and propagated it in athymic nude mouse footpads. Genomic analysis of this strain (NHDP-385) identified a unique repetitive element, RLPM, on which a specific real-time quantitative polymerase chain reaction assay was developed. The RLPM assay, and a previously developed RLEP quantitative polymerase chain reaction assay for M. leprae, were validated as clinical diagnostic assays according to Clinical Laboratory Improvement Amendments guidelines. We tested DNA from archived histological sections, patient specimens from the United States, Philippines, and Mexico, and US wild armadillos. RESULTS: The limit of detection for the RLEP and RLPM assays is 30 M. leprae per specimen (0.76 bacilli per reaction; coefficient of variation, 0.65%-2.44%) and 122 M. lepromatosis per specimen (3.05 bacilli per reaction; 0.84%-2.9%), respectively. In histological sections (n = 10), 1 lepromatous leprosy (LL), 1 DLL, and 3 Lucio reactions contained M. lepromatosis; 2 LL and 2 Lucio reactions contained M. leprae; and 1 LL reaction contained both species. M. lepromatosis was detected in 3 of 218 US biopsy specimens (1.38%). All Philippines specimens (n = 180) were M. lepromatosis negative and M. leprae positive. Conversely, 15 of 47 Mexican specimens (31.91%) were positive for M. lepromatosis, 19 of 47 (40.43%) were positive for M. leprae, and 2 of 47 (4.26%) contained both organisms. All armadillos were M. lepromatosis negative. CONCLUSIONS: The RLPM and RLEP assays will aid healthcare providers in the clinical diagnosis and surveillance of leprosy.


Subject(s)
Mycobacterium leprae , Mycobacterium , Animals , Humans , Mexico , Mice , Mycobacterium leprae/genetics , Pathology, Molecular
12.
J Drugs Dermatol ; 18(5): 468-469, 2019 May 01.
Article in English | MEDLINE | ID: mdl-31141856

ABSTRACT

Sorafenib is an oral multikinase inhibitor approved by the United States Food and Drug Administration for the treatment of advanced hepatocellular and renal cell carcinoma. Cases of sorafenib-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome have been reported in the literature. DRESS syndrome is a potentially fatal, drug-induced hypersensitivity reaction that occurs 2-8 weeks after drug exposure. DRESS syndrome presents with generalized morbilliform eruption, facial edema, eosinophilia, and end-organ damage. We present the first reported case of sorafenib toxicity mimicking DRESS syndrome in a patient with metastatic adrenocortical carcinoma presenting with fever, morbilliform rash, and transaminitis in the absence of eosinophilia three days following initiation of sorafenib therapy. It is critical that clinicians are equipped to accurately diagnose DRESS syndrome due to its high mortality rate and the morbidity associated with prolonged steroid therapy. J Drugs Dermatol. 2019;18(5):468-469.


Subject(s)
Adrenal Cortex Neoplasms/drug therapy , Adrenocortical Carcinoma/drug therapy , Antineoplastic Agents/toxicity , Drug-Related Side Effects and Adverse Reactions/diagnosis , Sorafenib/toxicity , Adrenal Cortex Neoplasms/pathology , Adrenocortical Carcinoma/secondary , Diagnosis, Differential , Drug Hypersensitivity Syndrome/diagnosis , Female , Humans , Middle Aged , Neoplasm Metastasis
13.
J Clin Invest ; 129(5): 1926-1939, 2019 04 02.
Article in English | MEDLINE | ID: mdl-30939123

ABSTRACT

IL-26 is an antimicrobial protein secreted by Th17 cells that has the ability to directly kill extracellular bacteria. To ascertain whether IL-26 contributes to host defense against intracellular bacteria, we studied leprosy, caused by the obligate intracellular pathogen Mycobacterium leprae, as a model. Analysis of leprosy skin lesions by gene expression profiling and immunohistology revealed that IL-26 was more strongly expressed in lesions from the self-limited tuberculoid compared with expression in progressive lepromatous patients. IL-26 directly bound to M. leprae in axenic culture and reduced bacteria viability. Furthermore, IL-26, when added to human monocyte-derived macrophages infected with M. leprae, entered the infected cell, colocalized with the bacterium, and reduced bacteria viability. In addition, IL-26 induced autophagy via the cytoplasmic DNA receptor stimulator of IFN genes (STING), as well as fusion of phagosomes containing bacilli with lysosomal compartments. Altogether, our data suggest that the Th17 cytokine IL-26 contributes to host defense against intracellular bacteria.


Subject(s)
Interleukins/immunology , Leprosy, Lepromatous/microbiology , Leprosy, Tuberculoid/microbiology , Th17 Cells/immunology , Autophagy , Cytokines/immunology , Gene Expression Profiling , Humans , Lysosomes/immunology , Lysosomes/microbiology , Macrophages/immunology , Monocytes/cytology , Mycobacterium leprae , Mycobacterium tuberculosis , Phagosomes/immunology , Recombinant Proteins/immunology , Signal Transduction
14.
JCI Insight ; 4(8)2019 04 18.
Article in English | MEDLINE | ID: mdl-30996142

ABSTRACT

DC, through the uptake, processing, and presentation of antigen, are responsible for activation of T cell responses to defend the host against infection, yet it is not known if they can directly kill invading bacteria. Here, we studied in human leprosy, how Langerhans cells (LC), specialized DC, contribute to host defense against bacterial infection. IFN-γ treatment of LC isolated from human epidermis and infected with Mycobacterium leprae (M. leprae) activated an antimicrobial activity, which was dependent on the upregulation of the antimicrobial peptide cathelicidin and induction of autophagy. IFN-γ induction of autophagy promoted fusion of phagosomes containing M. leprae with lysosomes and the delivery of cathelicidin to the intracellular compartment containing the pathogen. Autophagy enhanced the ability of M. leprae-infected LC to present antigen to CD1a-restricted T cells. The frequency of IFN-γ labeling and LC containing both cathelicidin and autophagic vesicles was greater in the self-healing lesions vs. progressive lesions, thus correlating with the effectiveness of host defense against the pathogen. These data indicate that autophagy links the ability of DC to kill and degrade an invading pathogen, ensuring cell survival from the infection while facilitating presentation of microbial antigens to resident T cells.


Subject(s)
Antigen Presentation , Autophagy , Langerhans Cells/immunology , Leprosy/immunology , Mycobacterium leprae/immunology , Antigens, Bacterial/immunology , Antimicrobial Cationic Peptides/immunology , Antimicrobial Cationic Peptides/metabolism , Autophagosomes/immunology , Autophagosomes/metabolism , Autophagosomes/microbiology , Biopsy , Cells, Cultured , Epidermis/immunology , Epidermis/microbiology , Epidermis/pathology , Humans , Interferon-gamma/immunology , Langerhans Cells/microbiology , Langerhans Cells/ultrastructure , Leprosy/microbiology , Leprosy/pathology , Lysosomes/immunology , Lysosomes/metabolism , Lysosomes/microbiology , Microscopy, Electron, Transmission , Mycobacterium leprae/isolation & purification , Primary Cell Culture , Recombinant Proteins/immunology , T-Lymphocytes/immunology , Up-Regulation/immunology , Cathelicidins
15.
JCI Insight ; 1(15): e88843, 2016 09 22.
Article in English | MEDLINE | ID: mdl-27699251

ABSTRACT

Transcriptome profiles derived from the site of human disease have led to the identification of genes that contribute to pathogenesis, yet the complex mixture of cell types in these lesions has been an obstacle for defining specific mechanisms. Leprosy provides an outstanding model to study host defense and pathogenesis in a human infectious disease, given its clinical spectrum, which interrelates with the host immunologic and pathologic responses. Here, we investigated gene expression profiles derived from skin lesions for each clinical subtype of leprosy, analyzing gene coexpression modules by cell-type deconvolution. In lesions from tuberculoid leprosy patients, those with the self-limited form of the disease, dendritic cells were linked with MMP12 as part of a tissue remodeling network that contributes to granuloma formation. In lesions from lepromatous leprosy patients, those with disseminated disease, macrophages were linked with a gene network that programs phagocytosis. In erythema nodosum leprosum, neutrophil and endothelial cell gene networks were identified as part of the vasculitis that results in tissue injury. The present integrated computational approach provides a systems approach toward identifying cell-defined functional networks that contribute to host defense and immunopathology at the site of human infectious disease.


Subject(s)
Gene Regulatory Networks , Leprosy/genetics , Leprosy/immunology , Adolescent , Adult , Erythema Nodosum/genetics , Erythema Nodosum/immunology , Female , Humans , Leprosy, Lepromatous/genetics , Leprosy, Lepromatous/immunology , Leprosy, Tuberculoid/genetics , Leprosy, Tuberculoid/immunology , Male , Middle Aged , Transcriptome , Young Adult
16.
PLoS Pathog ; 12(6): e1005705, 2016 06.
Article in English | MEDLINE | ID: mdl-27355424

ABSTRACT

Triggering antimicrobial mechanisms in macrophages infected with intracellular pathogens, such as mycobacteria, is critical to host defense against the infection. To uncover the unique and shared antimicrobial networks induced by the innate and adaptive immune systems, gene expression profiles generated by RNA sequencing (RNAseq) from human monocyte-derived macrophages (MDMs) activated with TLR2/1 ligand (TLR2/1L) or IFN-γ were analyzed. Weighed gene correlation network analysis identified modules of genes strongly correlated with TLR2/1L or IFN-γ that were linked by the "defense response" gene ontology term. The common TLR2/1L and IFN-γ inducible human macrophage host defense network contained 16 antimicrobial response genes, including S100A12, which was one of the most highly induced genes by TLR2/1L. There is limited information on the role of S100A12 in infectious disease, leading us to test the hypothesis that S100A12 contributes to host defense against mycobacterial infection in humans. We show that S100A12 is sufficient to directly kill Mycobacterium tuberculosis and Mycobacterium leprae. We also demonstrate that S100A12 is required for TLR2/1L and IFN-γ induced antimicrobial activity against M. leprae in infected macrophages. At the site of disease in leprosy, we found that S100A12 was more strongly expressed in skin lesions from tuberculoid leprosy (T-lep), the self-limiting form of the disease, compared to lepromatous leprosy (L-lep), the progressive form of the disease. These data suggest that S100A12 is part of an innate and adaptive inducible antimicrobial network that contributes to host defense against mycobacteria in infected macrophages.


Subject(s)
Leprosy/immunology , Macrophages/immunology , S100A12 Protein/immunology , Flow Cytometry , Fluorescent Antibody Technique , Gene Expression Profiling , Humans , Macrophages/microbiology , Mycobacterium Infections/immunology , Mycobacterium leprae/immunology , Mycobacterium tuberculosis/immunology , Real-Time Polymerase Chain Reaction , Transcriptome
17.
Lepr Rev ; 87(1): 130-1, 2016 Mar.
Article in English | MEDLINE | ID: mdl-27255071
18.
J Invest Dermatol ; 135(10): 2410-2417, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26030183

ABSTRACT

The mechanisms by which intracellular pathogens trigger immunosuppressive pathways are critical for understanding the pathogenesis of microbial infection. One pathway that inhibits host defense responses involves the induction of type I interferons and subsequently IL-10, yet the mechanism by which type I IFN induces IL-10 remains unclear. Our studies of gene expression profiles derived from leprosy skin lesions suggested a link between IL-27 and the IFN-ß induced IL-10 pathway. Here, we demonstrate that the IL-27p28 subunit is upregulated following treatment of monocytes with IFN-ß and Mycobacterium leprae, the intracellular bacterium that causes leprosy. The ability of IFN-ß and M. leprae to induce IL-10 was diminished by IL-27 knockdown. Additionally, treatment of monocytes with recombinant IL-27 was sufficient to induce the production of IL-10. Functionally, IL-27 inhibited the ability of IFN-γ to trigger antimicrobial activity against M. leprae in infected monocytes. At the site of disease, IL-27 was more strongly expressed in skin lesions of patients with progressive lepromatous leprosy, correlating and colocalizing with IFN-ß and IL-10 in macrophages. Together, these data provide evidence that in the human cutaneous immune responses to microbial infection, IL-27 contributes to the suppression of host antimicrobial responses.


Subject(s)
Interferon-beta/pharmacology , Interleukin-10/metabolism , Interleukin-27/metabolism , Leprosy, Lepromatous/drug therapy , Leprosy, Lepromatous/metabolism , Mycobacterium leprae/metabolism , Animals , Biomarkers/metabolism , Cells, Cultured , Cytokines/metabolism , Enzyme-Linked Immunosorbent Assay , Humans , Immunosuppressive Agents/pharmacology , Interleukin-27/pharmacology , Leprosy, Lepromatous/pathology , Mice , Microscopy, Confocal , Models, Animal , Monocytes/cytology , Monocytes/drug effects , Mycobacterium leprae/pathogenicity , Prognosis , RNA, Small Interfering/metabolism , Real-Time Polymerase Chain Reaction/methods , Sampling Studies , Sensitivity and Specificity , Transfection
19.
PLoS One ; 10(4): e0122723, 2015.
Article in English | MEDLINE | ID: mdl-25856343

ABSTRACT

Mucosal tissues are critical immune effector sites containing complex populations of leukocytes in a tissue microenvironment that remains incompletely understood. We identify and quantify in human distal colorectal tissue absolute mucosal CD3+ lymphocytes, including CD4+ and CD8+ subsets, by direct visualization using immunohistochemistry (IHC), immunofluorescence (IF), and an automated counting protocol (r2=0.90). Sigmoid and rectal mucosal tissues are both densely packed with T lymphocytes in the mucosal compartment. Both compartments had similar densities of CD3+ T lymphocytes with 37,400 ± 2,801 cells/mm3 and 33,700 ± 4,324 cell/mm3, respectively. Sigmoid mucosa contained 57% CD3+CD4+ and 40% CD3+CD8+ T lymphocytes which calculates to 21,300 ± 1,476/mm3 and 15,000 ± 275/mm3 T lymphocytes, respectively. Rectal mucosa had 57% CD3+CD4+ and 42% CD3+CD8+ or 21,577 ± 332, and 17,090 ± 1,206 cells/mm3, respectively. By comparison, sigmoid mucosal biopsies subjected to conventional collagenase digestion, mononuclear cell (MMC) isolation and staining for flow cytometry yielded 4,549 ± 381/mm3 and 2,708 ± 245/mm3 CD4+ and CD8+ T lymphocytes. These data suggest only ~20.7% recovery compared to IHC results for these markers. Further studies will determine if this reflects a selective bias in only CD3+, CD4+ and CD8+ T cells or can be generalized to all flow-analyzed cells from mucosal tissues for phenotyping and functional testing.


Subject(s)
Cell Separation/methods , Intestinal Mucosa/immunology , Intestine, Large/immunology , T-Lymphocyte Subsets/immunology , Cell Count , Flow Cytometry , Fluorescent Antibody Technique , Humans , Immunohistochemistry
20.
J Am Acad Dermatol ; 71(4): 795-803, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24767732

ABSTRACT

Immunologic reactions are an important aspect of leprosy that significantly impacts the course of the disease and the associated disability. Reversal reaction (type 1), erythema nodosum leprosum (type 2), and Lucio phenomenon are the 3 leprosy reactions, and they are most commonly seen in patients with the lepromatous and borderline categories of the disease. Because these forms of leprosy are the most common types seen in the United States, it is particularly important for physicians to be able to recognize and treat them. The reactions may occur before, during, or after treatment with multidrug therapy. Reversal reactions are the most common cause of nerve damage in leprosy, and erythema nodosum leprosum may also lead to neuritis. Although there have not been enough studies to confirm the most effective management regimens, treatment of reversal reaction and Lucio phenomenon with prednisone and of erythema nodosum leprosum with thalidomide and/or prednisone may help improve symptoms and prevent further disability.


Subject(s)
Erythema Nodosum/immunology , Leprostatic Agents/therapeutic use , Leprosy, Lepromatous/immunology , Leprosy/immunology , Biopsy, Needle , Disability Evaluation , Disease Progression , Drug Therapy, Combination , Erythema Nodosum/drug therapy , Erythema Nodosum/etiology , Erythema Nodosum/pathology , Humans , Immunohistochemistry , Immunologic Factors , Leprosy/complications , Leprosy/drug therapy , Leprosy/pathology , Leprosy, Lepromatous/drug therapy , Leprosy, Lepromatous/etiology , Male , Necrosis , Prednisone/therapeutic use , Prognosis , Risk Assessment , Severity of Illness Index , Vasculitis/drug therapy , Vasculitis/etiology , Vasculitis/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...